A GxP risk assessment answers a practical question: where should validation effort go? Without one, teams default to treating every system the same — which means over-validating low-impact tools while under-validating the systems that actually carry patient risk. Both outcomes are expensive, and only one of them is visible before an inspection.
Regulators have been explicit that they expect a risk-based approach. ICH Q9(R1), GAMP 5 Second Edition and the FDA's Computer Software Assurance guidance all say the same thing: effort should be proportionate to risk. This guide covers how to determine GxP impact, how to score risk defensibly, and how to convert that score into a validation plan rather than a filed document nobody uses.
Step one: is it GxP-relevant at all?
This is a binary determination, and it precedes any scoring. A system is GxP-relevant if it does any of the following:
- Creates, modifies, stores or transmits data used in a decision about product quality, patient safety or regulatory submission.
- Controls or monitors a process that affects product quality.
- Holds records that regulations require you to maintain and produce.
- Enforces a control that a regulation requires — access control, electronic signature, audit trail.
Record the rationale for every system, including the ones you determine are not GxP-relevant. Auditors ask about exclusions more often than inclusions, and "we decided it wasn't in scope" without a written basis is a weak position. See what makes a system GxP-relevant for the boundary cases.
Step two: score what could go wrong
The standard model, from ICH Q9, has three dimensions. Most teams handle the first two adequately and neglect the third, which is where the model actually earns its value.
Severity — if this function fails, what is the worst credible consequence? Anchor the scale in outcomes, not inconvenience: patient harm, a batch released that should not have been, a submission containing wrong data, a record that cannot be produced on request.
Probability — how likely is that failure? Consider complexity, maturity, degree of customisation, integration count, and how many people touch it.
Detectability — and this is the one that matters most. If the failure occurred, would you notice before harm resulted? A high-severity failure that is immediately obvious is often less dangerous than a moderate-severity failure that is silent. A miscalculation that produces an obviously absurd number gets caught. A miscalculation that produces a plausible number does not.
Assess at the level of function, not system. A LIMS is not one risk; sample login, result entry, calculation, specification comparison and release decision carry very different severities. Scoring at system level forces you to apply worst-case rigour to every function, which is exactly the over-validation the risk-based approach is meant to prevent.
Step three: turn the score into a plan
A risk assessment that does not change what you do is a document, not a control. The output should visibly determine effort.
- High risk — scripted testing with documented evidence, challenge and negative testing, formal traceability from requirement to test, independent review, and periodic revalidation on a defined interval.
- Medium risk — scripted testing of the critical paths, unscripted exploratory testing elsewhere, traceability maintained, review at change.
- Low risk — unscripted or exploratory testing, vendor evidence leveraged where the supplier is qualified, lightweight records.
This gradation is the core of Computer Software Assurance and of CSA services: critical thinking first, testing effort assigned accordingly, documentation sized to the evidence actually needed. The effort saved on low-risk functions is not saved — it is redeployed onto the high-risk ones, which is the argument that makes this defensible to a regulator.
What makes an assessment defensible
- The right people in the room. The process owner knows what failure means operationally; QA knows what it means regulatorily; IT knows what is technically plausible. An assessment authored by one function alone is the most common structural weakness.
- Written rationale, not just scores. A number without a sentence explaining it cannot be defended two years later when the author has left. The sentence is the deliverable; the score is shorthand for it.
- Consistent scale definitions. If "high severity" means different things in different assessments, the outputs cannot be compared and the prioritisation is arbitrary.
- Honest detectability. The temptation is to rate detectability optimistically because a monitoring control exists on paper. Ask who looks, how often, and what they would actually see.
- Revisited on change. A risk assessment frozen at go-live describes a system that no longer exists. New integration, new user population, new criticality — all of these change the answer.
Common failure modes
Reverse-engineering the score. Deciding the validation approach first and adjusting the risk rating to justify it. Auditors detect this by comparing assessments — when every system lands conveniently at medium, the pattern is visible.
Confusing business criticality with GxP risk. A system whose outage stops production is business-critical. That is not the same as a system whose silent malfunction lets bad product reach a patient. The second is the GxP risk.
Ignoring the integration. Two well-validated systems connected by an unassessed interface is a standard pattern for data integrity failures. The boundary is where records lose attribution.
Assessing the system and forgetting the process. The risk is rarely purely technical. A validated system operated by untrained people through an outdated procedure is a high-risk arrangement regardless of the software.
Once the scoring is sound, the effort shifts to producing and maintaining the evidence. That is where teams look at GxP software, and where GxP AI is increasingly used to draft risk assessments and trace them to tests for human review — a pattern set out in AI across the validation lifecycle.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
